These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 21655094)

  • 21. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
    Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H
    BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
    So KS; Kim CH; Rho JK; Kim SY; Choi YJ; Song JS; Kim WS; Choi CM; Chun YJ; Lee JC
    PLoS One; 2014; 9(12):e114000. PubMed ID: 25486409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
    Fong JT; Jacobs RJ; Moravec DN; Uppada SB; Botting GM; Nlend M; Puri N
    PLoS One; 2013; 8(11):e78398. PubMed ID: 24223799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
    Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
    PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer.
    Dragowska WH; Weppler SA; Wang JC; Wong LY; Kapanen AI; Rawji JS; Warburton C; Qadir MA; Donohue E; Roberge M; Gorski SM; Gelmon KA; Bally MB
    PLoS One; 2013; 8(10):e76503. PubMed ID: 24146879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
    Faber AC; Li D; Song Y; Liang MC; Yeap BY; Bronson RT; Lifshits E; Chen Z; Maira SM; García-Echeverría C; Wong KK; Engelman JA
    Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19503-8. PubMed ID: 19850869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.
    Puglisi M; Thavasu P; Stewart A; de Bono JS; O'Brien ME; Popat S; Bhosle J; Banerji U
    Lung Cancer; 2014 Aug; 85(2):141-6. PubMed ID: 24957682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R; Jiang H; Li J; Liu X; Xu H
    Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs.
    Lypova N; Dougherty SM; Lanceta L; Chesney J; Imbert-Fernandez Y
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
    Okamoto K; Okamoto I; Hatashita E; Kuwata K; Yamaguchi H; Kita A; Yamanaka K; Ono M; Nakagawa K
    Mol Cancer Ther; 2012 Jan; 11(1):204-13. PubMed ID: 22075159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.
    Kim Y; Ko J; Cui Z; Abolhoda A; Ahn JS; Ou SH; Ahn MJ; Park K
    Mol Cancer Ther; 2012 Mar; 11(3):784-91. PubMed ID: 22228822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
    Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
    Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
    Buck E; Eyzaguirre A; Haley JD; Gibson NW; Cagnoni P; Iwata KK
    Mol Cancer Ther; 2006 Aug; 5(8):2051-9. PubMed ID: 16928826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
    Karachaliou N; Codony-Servat J; Teixidó C; Pilotto S; Drozdowskyj A; Codony-Servat C; Giménez-Capitán A; Molina-Vila MA; Bertrán-Alamillo J; Gervais R; Massuti B; Morán T; Majem M; Felip E; Carcereny E; García-Campelo R; Viteri S; González-Cao M; Morales-Espinosa D; Verlicchi A; Crisetti E; Chaib I; Santarpia M; Luis Ramírez J; Bosch-Barrera J; Felipe Cardona A; de Marinis F; López-Vivanco G; Miguel Sánchez J; Vergnenegre A; Sánchez Hernández JJ; Sperduti I; Bria E; Rosell R
    Sci Rep; 2015 Dec; 5():17499. PubMed ID: 26639561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
    Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
    Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer.
    Xu X; Liu Y; Gong Q; Ma L; Wei W; Zhao L; Luo Z
    Cancer Chemother Pharmacol; 2024 Aug; 94(2):209-221. PubMed ID: 38609654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells.
    Wu K; Chang Q; Lu Y; Qiu P; Chen B; Thakur C; Sun J; Li L; Kowluru A; Chen F
    Oncotarget; 2013 Dec; 4(12):2430-8. PubMed ID: 24280348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy.
    To KKW; Wu WKK; Loong HHF
    Eur J Pharmacol; 2018 Mar; 823():19-26. PubMed ID: 29378193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.